Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 9/20 | 0.65 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.65 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.61 |
| ▸ | SOD3 | P08294 | 2/20 | 0.54 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10379383 | 1.00 | GNAO1 (0.65) | GNAO1GNAI3GNAI1CXCR4SOD3 | |
| SCHEMBL7336599 | 1.00 | GNAO1 (0.65) | GNAO1GNAI3GNAI1CXCR4SOD3 | |
| SCHEMBL5394694 | 1.00 | GNAO1 (0.65) | GNAO1GNAI3GNAI1CXCR4SOD3 | |
| SCHEMBL162842 | 1.00 | GNAO1 (0.65) | GNAO1GNAI3GNAI1CXCR4SOD3 | |
| SCHEMBL744931 | 1.00 | GNAO1 (0.65) | GNAO1GNAI3GNAI1CXCR4SOD3 | |
| SCHEMBL21581269 | 1.00 | GNAO1 (0.65) | GNAO1GNAI3GNAI1CXCR4SOD3 | |
| SCHEMBL21581281 | 1.00 | GNAO1 (0.65) | GNAO1GNAI3GNAI1CXCR4SOD3 | |
| SCHEMBL21581298 | 1.00 | GNAO1 (0.65) | GNAO1GNAI3GNAI1CXCR4SOD3 | |
| SCHEMBL21581259 | 1.00 | GNAO1 (0.65) | GNAO1GNAI3GNAI1CXCR4SOD3 | |
| SCHEMBL21581257 | 1.00 | GNAO1 (0.65) | GNAO1GNAI3GNAI1CXCR4SOD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250147425-A1 | STRIPPER COMPOSITION AND METHOD FOR FORMING PATTERN USING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-05-08 | — | — | US | claimed |
| CN-119937261-A | Release agent composition and method of forming pattern using the same | 三星显示有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| CN-112675927-B | Multi-piperazinium functionalized anion exchange membrane and preparation method thereof | 大连理工大学 | 2021-12-03 | — | — | CN | claimed |
| CN-112675927-A | Novel polypiperazinium functionalized anion exchange membrane and preparation method thereof | 大连理工大学 | 2021-04-20 | — | — | CN | claimed |
| CN-107286337-B | A kind of piperazine functionalized polyphenylene oxide alkaline anion-exchange membrane and preparation method thereof | 大连理工大学 | 2019-04-09 | — | — | CN | claimed |
| CN-108067191-A | For the reactor assembly of orthophosphates in Adsorption waste water | 北京益清源环保科技有限公司 | 2018-05-25 | — | — | CN | claimed |
| CN-102408395-A | Novel piperazine and homopiperazine derivatives, preparation method and application thereof | UNIV GUANGXI NORMAL | 2012-04-11 | — | — | CN | claimed |
| CN-1025999-C | Imidazo [4,5-B] quinolinyloxyalkanoic acid amides with enhanced water solubility | BRISTOL MYERS SQUIBB CO (US) | 1994-09-28 | — | — | CN | claimed |
| CN-1051359-A | Improved imidazo [4, the 5-b] quinolinyloxyalkanoic acid amides of water-soluble degree | BRISTOL MYERS SQUIBB CO (US) | 1991-05-15 | — | — | CN | claimed |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-03-17 | — | — | US | disclosed |
| US-20250147425-A1 | STRIPPER COMPOSITION AND METHOD FOR FORMING PATTERN USING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-05-08 | — | — | US | disclosed |
| CN-119937261-A | Release agent composition and method of forming pattern using the same | 三星显示有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250092067-A1 | APT1 and APT2 Inhibitors and Uses Thereof | CORNELL UNIVERSITY | 2025-03-20 | — | — | US | disclosed |
| CN-118956250-B | High-strength high-weather-resistance elastic coating and preparation method and application thereof | 天津森聚柯密封涂层材料有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-0049683-A2 | Imidazo-rifamycines, process for their preparation, pharmaceutical preparations containing them and their use | CIBA-GEIGY AG (CH) | 1982-04-14 | — | — | EP | disclosed |
| US-4306065-A | HYPOTENSIVE | A. H. ROBINS COMPANY, INCORPORATED (US) | 1981-12-15 | — | — | US | disclosed |
| US-4239759-A | Morpholino containing compounds, compositions and use thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1980-12-16 | — | — | US | disclosed |
| US-4110447-A | Anti-inflammatory (halo-4-biphenylyl)-alkanolamines | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1978-08-29 | — | — | US | disclosed |
| US-4051136-A | Piperazinyl cyclobutenones | G. D. SEARLE & CO. (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092067-A1 | APT1 and APT2 Inhibitors and Uses Thereof | LYPLA2, LYPLA1, PPT1 | GNAO1 1896/4885GNAI3 1943/4885GNAI1 820/4885 |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | CD38, PARP9, MCCC2 | GNAO1 3796/4885GNAI3 3555/4885GNAI1 2745/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | GNAO1 622/4885GNAI3 1124/4885GNAI1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.